

David Stepensky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1056267/publications.pdf>

Version: 2024-02-01

59
papers

2,114
citations

236833

25
h-index

243529

44
g-index

60
all docs

60
docs citations

60
times ranked

3298
citing authors

#	ARTICLE	IF	CITATIONS
1	Levetiracetam in lactation: How much is excreted into human breast milk?. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 199-205.	1.1	7
2	Magnitude of Lamotrigine Exposure Through Breastfeeding. <i>Breastfeeding Medicine</i> , 2022, 17, 341-348.	0.8	2
3	Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition. <i>Bioconjugate Chemistry</i> , 2022, 33, 795-806.	1.8	3
4	Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency. <i>International Journal of Pharmaceutics</i> , 2021, 592, 120012.	2.6	12
5	Combined Effects of Carotenoids and Polyphenols in Balancing the Response of Skin Cells to UV Irradiation. <i>Molecules</i> , 2021, 26, 1931.	1.7	21
6	Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. <i>Scientific Reports</i> , 2021, 11, 7676.	1.6	17
7	Therapeutic levetiracetam monitoring during pregnancy: â€œmind the gapâ€. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231985165.	1.1	14
8	Effect of Tomato Nutrient Complex on Blood Pressure: A Double Blind, Randomized Doseâ€“Response Study. <i>Nutrients</i> , 2019, 11, 950.	1.7	32
9	Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer. <i>Journal of Controlled Release</i> , 2018, 279, 1-7.	4.8	24
10	Pharmacokinetics of Toxin-Derived Peptide Drugs. <i>Toxins</i> , 2018, 10, 483.	1.5	19
11	Nuclear and perinuclear targeting efficiency of quantum dots depends on density of peptidic targeting residues on their surface. <i>Journal of Controlled Release</i> , 2017, 257, 32-39.	4.8	17
12	Imaging Cancer Cells Expressing the Folate Receptor with Carbon Dots Produced from Folic Acid. <i>ChemBioChem</i> , 2016, 17, 614-619.	1.3	114
13	Pharmacokinetics and Pharmacodynamics of Nano-Drug Delivery Systems. <i>Fundamental Biomedical Technologies</i> , 2016, , 341-362.	0.2	2
14	Delivery of Peptides and Proteins to the Brain Using Nano-Drug Delivery Systems and Other Formulations. <i>Advances in Delivery Science and Technology</i> , 2016, , 201-220.	0.4	1
15	Celecoxib interferes to a limited extent with aspirinâ€“mediated inhibition of platelets aggregation. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 316-326.	1.1	8
16	Efficient Subcellular Targeting to the Cell Nucleus of Quantum Dots Densely Decorated with a Nuclear Localization Sequence Peptide. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 2001-2009.	4.0	35
17	Limited Efficiency of Drug Delivery to Specific Intracellular Organelles Using Subcellularly â€œTargetedâ€“Drug Delivery Systems. <i>Molecular Pharmaceutics</i> , 2016, 13, 1-7.	2.3	46
18	In vitro toxicity of infusion sets depends on their composition, storage time and storage conditions. <i>International Journal of Pharmaceutics</i> , 2015, 489, 285-293.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 767-784.	1.5	9
20	Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 41-52.	1.5	11
21	Delivery of drugs to intracellular organelles using drug delivery systems: Analysis of research trends and targeting efficiencies. <i>International Journal of Pharmaceutics</i> , 2015, 496, 268-274.	2.6	39
22	Mechanisms of cell death induced by infusion sets leachables in in vitro experimental settings. <i>International Journal of Pharmaceutics</i> , 2015, 478, 693-701.	2.6	7
23	Beta-casein nanocarriers of celecoxib for improved oral bioavailability. <i>European Journal of Nanomedicine</i> , 2014, 6, .	0.6	25
24	Plasma and cerebrospinal fluid concentrations of ibuprofen in pediatric patients and antipyretic effect: Pharmacokinetic-pharmacodynamic modeling analysis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1023-1030.	1.0	15
25	Quantitative analysis of drug delivery to the brain via nasal route. <i>Journal of Controlled Release</i> , 2014, 189, 133-140.	4.8	245
26	Efficient Decoration of Nanoparticles Intended for Intracellular Drug Targeting with Targeting Residues, As Revealed by a New Indirect Analytical Approach. <i>Molecular Pharmaceutics</i> , 2014, 11, 2906-2914.	2.3	12
27	Pharmacokinetic and Pharmacodynamic Aspects of Focal and Targeted Delivery of Drugs. <i>Advances in Delivery Science and Technology</i> , 2014, , 149-166.	0.4	1
28	Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. <i>Journal of Controlled Release</i> , 2013, 171, 17-23.	4.8	38
29	Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 381-389.	2.0	36
30	Bolaamphiphilic vesicles encapsulating iron oxide nanoparticles: New vehicles for magnetically targeted drug delivery. <i>International Journal of Pharmaceutics</i> , 2013, 450, 241-249.	2.6	26
31	Prediction of Drug Disposition on the Basis of its Chemical Structure. <i>Clinical Pharmacokinetics</i> , 2013, 52, 415-431.	1.6	25
32	Local versus Systemic Anti-Tumour Necrosis Factor- α Effects of Adalimumab in Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2012, 51, 443-455.	1.6	16
33	Pharmacokinetics of Glutamate-Oxaloacetate Transaminase and Glutamate-Pyruvate Transaminase and Their Blood Glutamate-Lowering Activity in Na ⁺ -ve Rats. <i>Neurochemical Research</i> , 2012, 37, 2198-2205.	1.6	33
34	Toxicity assessment of extracts from infusion sets in cEND brain endothelial cells. <i>International Journal of Pharmaceutics</i> , 2012, 434, 20-27.	2.6	6
35	Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. <i>Journal of Controlled Release</i> , 2012, 160, 315-321.	4.8	43
36	The "Tozer" model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1233-1243.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Intracellular Targeting of PLGA Nanoparticles Encapsulating Antigenic Peptide to the Endoplasmic Reticulum of Dendritic Cells and Its Effect on Antigen Cross-Presentation <i>in Vitro</i> . <i>Molecular Pharmaceutics</i> , 2011, 8, 1266-1275.	2.3	93
38	â€œIntraCellâ€™ plugin for assessment of intracellular localization of nano-delivery systems and their targeting to the individual organelles. <i>Biochemical and Biophysical Research Communications</i> , 2011, 405, 228-233.	1.0	14
39	Use of unbound volumes of drug distribution in pharmacokinetic calculations. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 91-98.	1.9	15
40	Solubility and bioavailability of stabilized amorphous calcium carbonate. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 364-372.	3.1	66
41	Quantitative Aspects of Intracellularly-Targeted Drug Delivery. <i>Pharmaceutical Research</i> , 2010, 27, 2776-2780.	1.7	17
42	FRETcalc plugin for calculation of FRET in non-continuous intracellular compartments. <i>Biochemical and Biophysical Research Communications</i> , 2007, 359, 752-758.	1.0	31
43	Aggregate Formation by ERp57â€™Deficient MHC Class I Peptideâ€™Loading Complexes. <i>Traffic</i> , 2007, 8, 1530-1542.	1.3	21
44	O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. <i>Clinical and Experimental Immunology</i> , 2006, 143, 139-149.	1.1	38
45	Delivery of Gentamicin to the Rabbit Eye by Drug-Loaded Hydrogel Iontophoresis. , 2004, 45, 2543.		102
46	Longâ€™term stability study of Lâ€™adrenaline injections: Kinetics of sulfonation and racemization pathways of drug degradation. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 969-980.	1.6	27
47	Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. <i>International Journal of Pharmaceutics</i> , 2004, 277, 141-153.	2.6	103
48	Bone as an Effect Compartment. <i>Clinical Pharmacokinetics</i> , 2003, 42, 863-881.	1.6	50
49	Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 711-720.	1.0	49
50	Pharmacokinetic-Pharmacodynamic Analysis of the Glucose-Lowering Effect of Metformin in Diabetic Rats Reveals First-Pass Pharmacodynamic Effect. <i>Drug Metabolism and Disposition</i> , 2002, 30, 861-868.	1.7	112
51	Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 508-516.	1.6	14
52	A Signal Transduction Pharmacodynamic Model of the Kinetics of the Parasympathomimetic Activity of Low-Dose Scopolamine and Atropine in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2500-2510.	1.6	19
53	Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. <i>Pharmaceutical Research</i> , 2002, 19, 1516-1523.	1.7	61
54	Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination. <i>International Journal of Pharmaceutics</i> , 2001, 220, 1-11.	2.6	25

#	ARTICLE	IF	CITATIONS
55	Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine. <i>Pharmaceutical Research</i> , 2001, 18, 1220-1225.	1.7	7
56	Preclinical evaluation of pharmacokineticâ€“pharmacodynamic rationale for oral CR metformin formulation. <i>Journal of Controlled Release</i> , 2001, 71, 107-115.	4.8	115
57	A Peptide Prodrug Approach for Improving Bisphosphonate Oral Absorption. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3641-3652.	2.9	104
58	Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. <i>Pharmaceutical Research</i> , 1999, 16, 1399-1406.	1.7	19
59	Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1999, 16, 70.	1.2	44